HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $127

Benzinga · 2d ago
HC Wainwright & Co. analyst Douglas Tsao maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $120 to $127.